Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
Jarash, Jordan. In N Engl J Med, 23 Feb 2014
METHODS: We conducted two double-blind, randomized, placebo-controlled, phase 3 trials involving patients with mild-to-moderate Alzheimer's disease--one involving 1121 carriers of the apolipoprotein E (APOE) ε4 allele and the other involving 1331 noncarriers.
Mouse models of plaque rupture.
Fukuoka, Japan. In Curr Opin Lipidol, Oct 2013
Atherosclerotic plaques in the brachiocephalic arteries of apolipoprotein E (ApoE)-deficient mice fed a high-fat diet demonstrate several key histological features of ruptured human plaques.
What causes alzheimer's disease?
Birmingham, United Kingdom. In Folia Neuropathol, 2012
These include: (1) exacerbation of aging, (2) degeneration of anatomical pathways, including the cholinergic and cortico-cortical pathways, (3) an environmental factor such as exposure to aluminium, head injury, or malnutrition, (4) genetic factors including mutations of amyloid precursor protein (APP) and presenilin (PSEN) genes and allelic variation in apolipoprotein E (Apo E), (5) mitochondrial dysfunction, (6) a compromised blood brain barrier, (7) immune system dysfunction, and (8) infectious agents.